STOCK MARKET BSE NSE

Drug Controller clears Psoriasis injection for 'restricted emergency use' to treat COVID-19 patients

This will be used for restricted emergency use for the treatment of 'cytokine'' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.

Published: 11th July 2020 08:39 AM  |   Last Updated: 11th July 2020 08:43 AM   |  A+A-

Vaccine

Written informed consent of each patient is required before the use of this drug. (Representational Image)

By PTI

NEW DELHI: India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials said on Friday.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of "cytokine'' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

​CLICK HERE FOR COVID-19 LIVE UPDATES

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.

"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said.

ALSO WATCH:

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp